BR112014011981A2 - formulações farmacêuticas - Google Patents

formulações farmacêuticas

Info

Publication number
BR112014011981A2
BR112014011981A2 BR112014011981A BR112014011981A BR112014011981A2 BR 112014011981 A2 BR112014011981 A2 BR 112014011981A2 BR 112014011981 A BR112014011981 A BR 112014011981A BR 112014011981 A BR112014011981 A BR 112014011981A BR 112014011981 A2 BR112014011981 A2 BR 112014011981A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulations
treatment
formulations
diseases
relates
Prior art date
Application number
BR112014011981A
Other languages
English (en)
Other versions
BR112014011981B1 (pt
BR112014011981A8 (pt
BR112014011981B8 (pt
Inventor
Verma Daya
Lee Hanchen
Tan Laychoo
Li Ping
Singh Rajinder
Shen Xiaohong
Krishnamachari Yogita
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47501412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014011981(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014011981A2 publication Critical patent/BR112014011981A2/pt
Publication of BR112014011981A8 publication Critical patent/BR112014011981A8/pt
Publication of BR112014011981B1 publication Critical patent/BR112014011981B1/pt
Publication of BR112014011981B8 publication Critical patent/BR112014011981B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "formulações farmacêuticas". a presente invenção refere-se a formulações farmacêuticas orais sólidas de (1-((4-(3-(5-cloro-2-fluoro-3-(metilsulfonamido)fenil)-1-isopropil-1h-pirazol-4-il)pirimidin-2-il)amino)propan-2-il)carbamato de (s)-metila (composto a). a invenção refere-se ainda ao uso das referidas formulações farmacêuticas na preparação de medicamentos para o tratamento de uma doença proliferativa. são ainda descritos um uso e um método empregando estas formulações no tratamento de doenças proliferativas, tais como as doenças de tumores sólidos. 21131788v1 1/1 21131788v1
BR112014011981A 2011-11-23 2012-11-21 Formulações farmacêuticas sólidas orais, seus processos de preparação e usos BR112014011981B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563229P 2011-11-23 2011-11-23
US61/563,229 2011-11-23
PCT/US2012/066185 WO2013078264A1 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations

Publications (4)

Publication Number Publication Date
BR112014011981A2 true BR112014011981A2 (pt) 2017-05-30
BR112014011981A8 BR112014011981A8 (pt) 2018-07-31
BR112014011981B1 BR112014011981B1 (pt) 2020-11-17
BR112014011981B8 BR112014011981B8 (pt) 2022-07-19

Family

ID=47501412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011981A BR112014011981B8 (pt) 2011-11-23 2012-11-21 Formulações farmacêuticas sólidas orais, seus processos de preparação e usos

Country Status (38)

Country Link
US (4) US9387208B2 (pt)
EP (2) EP2782557B1 (pt)
JP (2) JP6216325B2 (pt)
KR (1) KR102091295B1 (pt)
CN (2) CN105708819B (pt)
AR (1) AR088936A1 (pt)
AU (1) AU2012340759C1 (pt)
BR (1) BR112014011981B8 (pt)
CA (1) CA2856406C (pt)
CL (1) CL2014001337A1 (pt)
CO (1) CO6940426A2 (pt)
CY (1) CY1121421T1 (pt)
DK (1) DK2782557T3 (pt)
EA (1) EA025389B1 (pt)
EC (1) ECSP23034537A (pt)
ES (2) ES3037966T3 (pt)
GT (1) GT201400100A (pt)
HR (1) HRP20181896T1 (pt)
HU (1) HUE040370T2 (pt)
IL (1) IL232305B (pt)
JO (1) JO3493B1 (pt)
LT (1) LT2782557T (pt)
MA (1) MA35716B1 (pt)
MX (1) MX353446B (pt)
MY (1) MY172729A (pt)
PE (1) PE20141994A1 (pt)
PH (1) PH12014501157A1 (pt)
PL (1) PL2782557T3 (pt)
PT (1) PT2782557T (pt)
RS (1) RS58048B1 (pt)
SG (1) SG11201401260QA (pt)
SI (1) SI2782557T1 (pt)
SM (1) SMT201800595T1 (pt)
TN (1) TN2014000145A1 (pt)
TW (1) TWI649098B (pt)
UA (1) UA115039C2 (pt)
WO (1) WO2013078264A1 (pt)
ZA (1) ZA201402418B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
WO2013078264A1 (en) 2011-11-23 2013-05-30 Novartis Ag Pharmaceutical formulations
BR112017025398A2 (pt) 2015-06-04 2018-08-07 Pfizer Inc. formas de dosagem sólidas de palbociclib
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
CN109078006B (zh) 2016-03-29 2021-04-20 深圳市药欣生物科技有限公司 一种帕布昔利布的药物制剂及其制备方法
BR112018074941A2 (pt) 2016-06-03 2019-03-12 Caponigro Giordano combinações farmacêuticas
CN106000220A (zh) * 2016-06-30 2016-10-12 东华大学 一种含化学试剂的有机溶剂崩解片的制备方法与应用
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
EP4225307A1 (en) 2020-10-05 2023-08-16 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
CN114557977A (zh) * 2022-02-16 2022-05-31 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
TR2022009483A2 (tr) * 2022-06-08 2023-12-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Palbosiklib içeren bir farmasötik bileşim.
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib
WO2025262137A1 (en) * 2024-06-21 2025-12-26 Nanoform Finland Oyj Formulations comprising crystalline nanosized encorafenib

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
WO1997008950A1 (en) 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP2002508754A (ja) 1997-05-22 2002-03-19 ジー ディ サール アンド カンパニ ｐ３８キナーゼ阻害剤としての置換基を有するピラゾール類
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
EP1239831B1 (en) 1999-12-23 2012-10-31 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1456180B1 (en) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EP1706400A1 (en) 2004-01-09 2006-10-04 Novartis AG Phenyl- 4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl -amine derivatives as igf-ir inhibitors
ES2396135T3 (es) 2004-06-10 2013-02-19 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas
US7608635B2 (en) 2005-08-12 2009-10-27 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
EP1919460A2 (en) 2005-08-22 2008-05-14 Novartis AG Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
EP1917258A2 (en) 2005-08-26 2008-05-07 SmithKline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
CA2643066A1 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
MX2009003456A (es) 2006-10-02 2009-04-14 Irm Llc Compuestos y composiciones como inhibidores de proteina cinasa.
CN101522026A (zh) 2006-10-06 2009-09-02 Irm责任有限公司 蛋白激酶抑制剂及其应用方法
MX2009004861A (es) 2006-11-09 2009-05-21 Abbott Gmbh & Co Kg Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
US20090022789A1 (en) * 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
KR20100038119A (ko) 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
UA100865C2 (ru) * 2007-10-19 2013-02-11 Эбботт Гмбх Унд Ко. Кг Твердый дисперсный продукт лекарственных средств на основе n-арилмочевины
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
BRPI0908906A2 (pt) 2008-03-21 2019-09-24 Novartis Ag compostos heterocíclicos e usos dos mesmos
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
PL2324008T3 (pl) 2008-07-24 2012-09-28 Nerviano Medical Sciences Srl 3,4-diarylopirazole jako inhibitory kinazy białkowej
AU2009276699A1 (en) 2008-07-28 2010-02-04 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
JP5603869B2 (ja) 2008-09-29 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
BR122021018683B1 (pt) * 2008-10-07 2022-11-16 Kudos Pharmaceuticals Limited Formulação farmacêutica de 4-[3-(4-ciclopropanocarbonil- piperazina-1-carbonil)-4-flúor- benzil]-2h-ftalazin-1-ona, uso de um polímero de matriz, forma de dosagem e método para produzir uma dispersão amorfa sólida
WO2010056662A1 (en) 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
WO2010070060A1 (en) 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
WO2010145998A1 (en) 2009-06-15 2010-12-23 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
CN104958294A (zh) 2010-01-27 2015-10-07 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
JP5938038B2 (ja) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
DK2688572T3 (en) 2011-03-21 2017-06-12 Valcuria Ab PHARMACEUTICAL COMPOSITION WITH AN HDAC INHIBITOR AND A STEROID AND USE THEREOF
CA2844407A1 (en) 2011-06-14 2012-12-20 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
WO2013078264A1 (en) 2011-11-23 2013-05-30 Novartis Ag Pharmaceutical formulations
RU2015121367A (ru) 2012-11-08 2017-01-10 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний

Also Published As

Publication number Publication date
US20140309250A1 (en) 2014-10-16
EP3449911A1 (en) 2019-03-06
HK1197024A1 (en) 2015-01-02
SI2782557T1 (sl) 2019-02-28
SG11201401260QA (en) 2014-07-30
JP6216325B2 (ja) 2017-10-18
ECSP23034537A (es) 2023-08-31
AU2012340759A1 (en) 2014-05-29
CL2014001337A1 (es) 2014-10-24
CA2856406C (en) 2020-06-23
TWI649098B (zh) 2019-02-01
JO3493B1 (ar) 2020-07-05
JP2015501808A (ja) 2015-01-19
TN2014000145A1 (en) 2015-09-30
KR102091295B1 (ko) 2020-03-19
KR20140095500A (ko) 2014-08-01
EA201491007A1 (ru) 2014-08-29
US10258622B2 (en) 2019-04-16
US20170202837A1 (en) 2017-07-20
CN105708819A (zh) 2016-06-29
PT2782557T (pt) 2018-11-26
ES3037966T3 (en) 2025-10-08
PL2782557T3 (pl) 2019-03-29
TW201328722A (zh) 2013-07-16
MX2014006278A (es) 2014-07-09
WO2013078264A1 (en) 2013-05-30
JP2018035171A (ja) 2018-03-08
AR088936A1 (es) 2014-07-16
SMT201800595T1 (it) 2019-01-11
US20190054086A1 (en) 2019-02-21
IL232305A0 (en) 2014-06-30
IL232305B (en) 2019-06-30
BR112014011981B1 (pt) 2020-11-17
US20160279129A1 (en) 2016-09-29
EP3449911B8 (en) 2025-07-23
ES2695099T3 (es) 2019-01-02
PH12014501157B1 (en) 2014-08-11
PH12014501157A1 (en) 2014-08-11
US9387208B2 (en) 2016-07-12
BR112014011981A8 (pt) 2018-07-31
CO6940426A2 (es) 2014-05-09
DK2782557T3 (en) 2018-12-10
RS58048B1 (sr) 2019-02-28
LT2782557T (lt) 2018-12-27
CN103945831A (zh) 2014-07-23
EP2782557B1 (en) 2018-09-12
CN105708819B (zh) 2020-12-29
US9763941B2 (en) 2017-09-19
EP2782557A1 (en) 2014-10-01
HUE040370T2 (hu) 2019-03-28
BR112014011981B8 (pt) 2022-07-19
HRP20181896T1 (hr) 2019-02-22
AU2012340759B2 (en) 2016-04-28
NZ623628A (en) 2016-05-27
EA025389B1 (ru) 2016-12-30
EP3449911B1 (en) 2025-06-18
PE20141994A1 (es) 2014-12-24
AU2012340759C1 (en) 2019-11-28
MA35716B1 (fr) 2014-12-01
GT201400100A (es) 2017-09-28
MX353446B (es) 2018-01-12
CA2856406A1 (en) 2013-05-30
UA115039C2 (uk) 2017-09-11
CY1121421T1 (el) 2020-05-29
MY172729A (en) 2019-12-11
ZA201402418B (en) 2015-03-25
US10561654B2 (en) 2020-02-18

Similar Documents

Publication Publication Date Title
BR112014011981A8 (pt) Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
BR112015006828A8 (pt) composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
EA201500430A1 (ru) Соединения боронатного эфира и его фармацевтические составы
UA107814C2 (uk) Спірооксіндольні антагоністи мdм2
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
UA117154C2 (uk) Антагоністи s1p3
WO2015048503A3 (en) N-arylmethyl sulfonamide negative modulators of nr2a
CY1111361T1 (el) Νεα προσδεματα συναγωνιστες των υποδοχεων rar, χρηση στην ανθρωπινη ιατρικη καθως και στην κοσμετολογια
CL2008001615A1 (es) Compuestos derivados de di(hetero)aril-ciclohexano; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cardiopatias, arritmias, isquemias, entre otras.
UA112981C2 (uk) Варіант людського gdnf
CL2013000655A1 (es) Compuestos derivados de fenoxidihidrobenzoxatiazepinas, moduladores de receptores ampa; composicion farmaceutica; procedimiento para preparalos; compuestos intermediarios; y su uso para el tratamiento o prevencion de trastornos mnemocognitivos asociados a la edad, sindromes ansiosos o depresivos y alzheimer, entre otras enfermedades.
TH104292B (th) สูตรผสมทางเภสัชกรรม
TR201105424A2 (tr) Çinko etken maddeli bir farmasötik formülasyon.
EA201390619A1 (ru) 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ARRAY BIOPHARMA, INC. (US)

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 870180031808 DE 19/04/2018, COM BASE NO DISPOSTO NO ART. 219, II DA LEI DA PROPRIEDADE INDUSTRIAL, HAJA VISTA QUE O INTERESSADO NAO TEM LEGITIMIDADE PARA O ATO.

B150 Others concerning applications: publication cancelled [chapter 15.30 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 15.7 NA RPI NO 2508 DE 29/01/2019 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/14 , A61K 9/20 , A61K 9/48

Ipc: A61K 31/506 (2006.01), A61K 9/00 (2006.01), A61K 9

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/11/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2602 DE 17/11/2020, QUANTO AO ITEM (73) NOME DO TITULAR.